Can-Fite BioPharma Ltd. (CANF)
NYSE American
$2.16−$0.0080 (−0.37%) on the dayAs of the close; data may be delayed.
CANF price, last 12 months
Key stats
- Previous close
- $2.17
- Open
- $2.22
- Day range
- $2.15 – $2.22
- 52-week range
- $2.15 – $12.80
- Volume
- 28.7K
- Avg volume (20 days)
- 1.1M
- Market cap
- $4.6M
Performance
1W−3.5%
1M−34.9%
3M−21.4%
6M−34.3%
YTD−46.0%
1Y−82.5%
vs S&P 500, 1Y−99.3 pts
Technicals and fundamentals
About Can-Fite BioPharma Ltd.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
- Listed on
- NYSE American
- Market cap
- $4.6M